Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13906103 | 1.00 | LMNA (0.31) | LMNACYP2C9 | |
| SCHEMBL13998202 | 0.85 | — | — | |
| SCHEMBL18406694 | 0.74 | STAT3 (0.44) | — | |
| SCHEMBL14010918 | 0.69 | — | — | |
| SCHEMBL14010716 | 0.62 | — | — | |
| SCHEMBL10042275 | 0.59 | STAT3 (0.50) | — | |
| SCHEMBL5078178 | 0.54 | LMNA (0.44) | LMNACYP2C9 | |
| SCHEMBL1924154 | 0.53 | LMNA (0.35) | LMNACYP2C9 | |
| SCHEMBL12438024 | 0.53 | LMNA (0.52) | LMNACYP2C9 | |
| SCHEMBL22877665 | 0.50 | LMNA (0.44) | LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | HCCS, HAVCR2, PYGL | LMNA 131/4885CYP2C9 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.